Gelonghui November 12th | Jenkem Technology (688356.SH) announced that its independently developed injection polyethylene glycol Iletikan (pharmaceutical code: JK1201I) for the treatment of triple-negative breast cancer with brain metastasis has completed the first subject enrollment in the phase II clinical trial "JK1201I treatment of triple-negative breast cancer with brain metastasis Phase II clinical study" recently.
键凯科技(688356.SH)：聚乙二醇伊立替康用于治疗伴脑转移的三阴性乳腺癌II期临床试验完成首例受试者入组
Jenkem technology (688356.SH): The first subject enrolled in the Phase II clinical trial of Polyethylene Glycol Ilibycin for the treatment of triple-negative breast cancer with brain metastases completed.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated